MCID: LNG015
MIFTS: 44

Lingual-Facial-Buccal Dyskinesia

Categories: Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lingual-Facial-Buccal Dyskinesia

MalaCards integrated aliases for Lingual-Facial-Buccal Dyskinesia:

Name: Lingual-Facial-Buccal Dyskinesia 11 14 71
Orofacial Dyskinesia 28 5
Oro-Facial Dyskinesia 11
Dyskinesias 43

Classifications:



External Ids:

Disease Ontology 11 DOID:9854
ICD9CM 34 333.82
MeSH 43 D020820
SNOMED-CT 68 267689009
ICD10 31 G24.4
UMLS 71 C0152115

Summaries for Lingual-Facial-Buccal Dyskinesia

MalaCards based summary: Lingual-Facial-Buccal Dyskinesia, also known as orofacial dyskinesia, is related to episodic ataxia and parkinson disease, late-onset, and has symptoms including spasmodic torticollis An important gene associated with Lingual-Facial-Buccal Dyskinesia is VPS13A (Vacuolar Protein Sorting 13 Homolog A), and among its related pathways/superpathways are Dopamine-DARPP32 Feedback onto cAMP Pathway and Monoamine GPCRs. The drugs Aripiprazole and Varenicline have been mentioned in the context of this disorder. Affiliated tissues include subthalamic nucleus, lung and brain, and related phenotypes are nervous system and growth/size/body region

Related Diseases for Lingual-Facial-Buccal Dyskinesia

Diseases related to Lingual-Facial-Buccal Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)
# Related Disease Score Top Affiliating Genes
1 episodic ataxia 30.3 LGI1 FGF14 CNTNAP2
2 parkinson disease, late-onset 30.2 SLC6A3 SLC18A2 HTR2C GRIN2B DRD3 DRD2
3 viral encephalitis 30.2 PNMA2 LGI1 CNTNAP2
4 basal ganglia disease 30.0 XPR1 SLC20A2 MYORG
5 stuttering 30.0 SLC6A3 DRD2 CNTNAP2
6 amnestic disorder 29.9 LGI1 GRIN2B CNTNAP2
7 tic disorder 29.9 SLC6A3 SLC18A2 DRD3 DRD2 CNTNAP2
8 neuroacanthocytosis 29.7 VPS13A PANK2 KEL
9 chronic tic disorder 29.7 SLC18A2 DRD2 CNTNAP2
10 choreoacanthocytosis 29.7 VPS13A PANK2 KEL
11 benign epilepsy with centrotemporal spikes 29.7 LGI1 GRIN2B GRIN1 CNTNAP2
12 pathological gambling 29.7 SLC6A3 DRD3 DRD2
13 post-traumatic stress disorder 29.7 SLC6A3 GRIN2B DRD2
14 huntington disease 29.7 VPS13A SLC6A3 GRIN2B GRIN1 DRD2
15 migraine with or without aura 1 29.7 SLC6A3 HTR2C GRIN2B DRD3 DRD2
16 bulimia nervosa 29.7 SLC6A3 HTR2C DRD2
17 alcohol use disorder 29.6 SLC6A3 GRIN2B DRD3 DRD2
18 toxic encephalopathy 29.6 SLC6A3 SLC18A2 GRIN2B
19 autism 29.5 SLC6A3 GRIN2B GRIN1 FGF14 DRD3 DRD2
20 speech and communication disorders 29.5 SLC6A3 LGI1 GRIN2B CNTNAP2
21 oromandibular dystonia 29.4 VPS13A PANK2
22 gilles de la tourette syndrome 29.4 SLC6A3 SLC18A2 DRD3 DRD2 CNTNAP2
23 cerebellar disease 29.4 FGF14 DPYSL5 CNTNAP2
24 focal dystonia 29.3 SLC6A3 PANK2 DRD2
25 cocaine abuse 29.2 SLC6A3 SLC18A2 DRD3 DRD2
26 impulse control disorder 29.2 SLC6A3 SLC18A2 GRIN2B DRD3 DRD2
27 supranuclear palsy, progressive, 1 29.2 SLC6A3 SLC18A2 IGLON5 DRD2
28 obsessive-compulsive disorder 29.2 SLC6A3 HTR2C GRIN2B DRD3 DRD2 CNTNAP2
29 limbic encephalitis 29.1 PNMA2 LGI1 IGLON5 GRIN2B DPYSL5 CNTNAP2
30 speech disorder 29.1 SLC6A3 LGI1 GRIN2B GRIN1 DRD2 CNTNAP2
31 anxiety 29.1 SLC6A3 HTR2C GRIN2B DRD3 DRD2
32 autism spectrum disorder 29.0 SLC6A3 GRIN2B DRD3 DRD2 CNTNAP2
33 attention deficit-hyperactivity disorder 29.0 SLC6A3 SLC18A2 HTR2C GRIN2B DRD3 DRD2
34 psychotic disorder 29.0 SLC6A3 SLC18A2 HTR2C GRIN2B GRIN1 DRD3
35 mutism 28.9 SLC6A3 PNMA2 LGI1 IGLON5 GRIN1 DPYSL5
36 schizophrenia 28.8 SLC6A3 SLC18A2 HTR2C GRIN2B GRIN1 DRD3
37 alcohol dependence 28.8 SLC6A3 SLC18A2 HTR2C GRIN2B GRIN1 DRD3
38 movement disease 28.7 VPS13A SLC6A3 SLC18A2 PANK2 LGI1 IGLON5
39 bipolar disorder 28.6 SLC6A3 SLC18A2 HTR2C GRIN2B GRIN1 DRD3
40 parkinsonism 28.5 XPR1 SLC6A3 SLC20A2 SLC18A2 PANK2 MYORG
41 dystonia 28.2 XPR1 VPS13A SLC6A3 SLC20A2 SLC18A2 PANK2
42 choreatic disease 27.5 VPS13A SLC6A3 SLC20A2 SLC18A2 PNMA2 PANK2
43 tardive dyskinesia 11.5
44 paroxysmal dyskinesia 11.3
45 dyskinesia, limb and orofacial, infantile-onset 11.3
46 dyskinesia with orofacial involvement, autosomal recessive 11.2
47 dystonia 31 11.2
48 spinocerebellar ataxia 27 11.1
49 myopathy with extrapyramidal signs 11.1
50 neurodevelopmental disorder with hyperkinetic movements and dyskinesia 11.1

Graphical network of the top 20 diseases related to Lingual-Facial-Buccal Dyskinesia:



Diseases related to Lingual-Facial-Buccal Dyskinesia

Symptoms & Phenotypes for Lingual-Facial-Buccal Dyskinesia

UMLS symptoms related to Lingual-Facial-Buccal Dyskinesia:


spasmodic torticollis

MGI Mouse Phenotypes related to Lingual-Facial-Buccal Dyskinesia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.2 CNTNAP2 DPYSL5 DRD2 DRD3 FGF14 GRIN1
2 growth/size/body region MP:0005378 9.97 CNTNAP2 DRD2 DRD3 FGF14 GRIN1 GRIN2B
3 behavior/neurological MP:0005386 9.83 CNTNAP2 DPYSL5 DRD2 DRD3 FGF14 GRIN1
4 muscle MP:0005369 9.8 DRD2 FGF14 HTR2C KEL PANK2 SLC18A2
5 taste/olfaction MP:0005394 9.02 CNTNAP2 DRD2 GRIN1 SLC18A2 SLC6A3

Drugs & Therapeutics for Lingual-Facial-Buccal Dyskinesia

Drugs for Lingual-Facial-Buccal Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
3
Levetiracetam Approved Phase 4 102767-28-2 441341 5284583
4
Carbidopa Approved Phase 4 28860-95-9 34359 38101
5
Amisulpride Approved, Investigational Phase 4 71675-85-9, 53583-79-2 2159
6
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
7
Galantamine Approved Phase 4 357-70-0, 1953-04-4 9651
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
10
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
11 Nicotinic Agonists Phase 4
12 Psychotropic Drugs Phase 4
13 Antipsychotic Agents Phase 4
14 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
15 Nootropic Agents Phase 4
16 Dopamine Antagonists Phase 4
17 Antidepressive Agents Phase 4
18 Gastrointestinal Agents Phase 4
19 Omega 3 Fatty Acid Phase 4
20 Antiemetics Phase 4
21 Serotonin Uptake Inhibitors Phase 4
22 Cholinesterase Inhibitors Phase 4
23 calcium channel blockers Phase 4
24
abobotulinumtoxinA Phase 4
25 Botulinum Toxins, Type A Phase 4
26 Botulinum Toxins Phase 4
27 Cholinergic Agents Phase 4
28
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
29
Buspirone Approved, Investigational Phase 3 36505-84-7 2477
30
Amantadine Approved Phase 3 768-94-5 2130
31
Ropinirole Approved, Investigational Phase 3 91374-21-9 5095
32
Tetrabenazine Approved, Investigational Phase 3 58-46-8 6018
33
Piracetam Approved, Investigational Phase 3 7491-74-9 4843
34 Anti-Anxiety Agents Phase 3
35 Carbidopa, levodopa drug combination Phase 3
36 Analgesics Phase 3
37 Adjuvants, Immunologic Phase 3
38 Immunologic Factors Phase 3
39 Antiviral Agents Phase 3
40 Anti-Infective Agents Phase 3
41 Analgesics, Non-Narcotic Phase 3
42 Cardiac Glycosides Phase 3
43
Ginkgo Phase 3
44 Neuroprotective Agents Phase 3
45
Phenylephrine Approved Phase 2 59-42-7 6041
46
Oxymetazoline Approved, Investigational Phase 2 1491-59-4 4636
47
Amitriptyline Approved Phase 2 50-48-6 2160
48
Pimavanserin Approved, Investigational Phase 2 706779-91-1 10071196
49
Entacapone Approved, Investigational Phase 2 130929-57-6 5281081
50
Nicotine Approved Phase 1, Phase 2 54-11-5 942 89594

Interventional clinical trials:

(show top 50) (show all 239)
# Name Status NCT ID Phase Drugs
1 Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study Unknown status NCT00837707 Phase 4 aripiprazole
2 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
3 Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response Unknown status NCT03495024 Phase 4 Varenicline
4 Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics Completed NCT00888186 Phase 4 levodopa/carbidopa
5 Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study Completed NCT00307450 Phase 4 Levetiracetam
6 A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Completed NCT03891862 Phase 4 Valbenazine;Placebo oral capsule
7 A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Completed NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
8 A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
9 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
10 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
11 Validation of Dyskinesia Rating Scales Completed NCT01071395 Phase 4 Amantadine;Placebo
12 A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine
13 An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease Suspended NCT03034538 Phase 4 Zonegran
14 Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study Terminated NCT00477802 Phase 4
15 Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial Unknown status NCT02617017 Phase 3 Buspirone;Placebo
16 Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease Unknown status NCT00260793 Phase 3 Ropinirole Hydrochloride
17 A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects. Completed NCT00363727 Phase 3 ropinirole controlled-release (REQUIP CR) for RLS
18 Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects Completed NCT00360568 Phase 3 Levodopa-carbidopa intestinal gel
19 A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00672373 Phase 3 Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
20 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
21 Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Completed NCT02736955 Phase 3 Valbenazine
22 An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication) Completed NCT02799381 Phase 3 Optimized antiparkinsonian treatment;Levodopa-Carbidopa Intestinal Gel (LCIG)
23 ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study) Completed NCT02274766 Phase 3 ADS-5102
24 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3 NBI-98854;Placebo
25 A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents Completed NCT03813238 Phase 3 Deutetrabenazine;Placebo
26 Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study) Completed NCT02136914 Phase 3 ADS-5102
27 A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Completed NCT00105508 Phase 3 Sarizotan;Placebo
28 A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT) Completed NCT03176771 Phase 2, Phase 3 MT-5199;Placebo
29 Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study Completed NCT00190008 Phase 3 piracetam
30 A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia Completed NCT00105521 Phase 3 Sarizotan;Placebo
31 A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3 NBI-98854
32 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3 levetiracetam;placebo
33 Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) Completed NCT01397422 Phase 2, Phase 3 ADS-5102 (extended release amantadine HCl)
34 Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID) Completed NCT02202551 Phase 3 ADS-5102
35 An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02198794 Phase 3 SD-809;Placebo
36 A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
37 Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
38 Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy Recruiting NCT04857359 Phase 2, Phase 3 Dipraglurant;Placebo
39 An Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications Recruiting NCT05116813 Phase 2, Phase 3 Dipraglurant
40 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Recruiting NCT05206513 Phase 3 Placebo;Valbenazine
41 A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias Terminated NCT02153645 Phase 3 240mg Amantadine HCl ER tablets;Placebo tablets;320mg Amantadine HCl ER tablets
42 A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias Terminated NCT02153632 Phase 3 amantadine HCl ER;Placebo
43 Pyridoxal Kinase Activity in Schizophrenia Patients Without Versus With Tardive Dyskinesia Treated With Vitamin B6 Withdrawn NCT01908452 Phase 3 Pyridoxine
44 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Withdrawn NCT03254186 Phase 2, Phase 3 Propranolol Hydrochloride;Placebo Oral Tablet
45 A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations Withdrawn NCT03987750 Phase 3 Safinamide Methanesulfonate 150mg;Safinamide Methanesulfonate 100mg;Safinamide Methanesulfonate matching placebo
46 Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial Unknown status NCT00291733 Phase 2 Levetiracetam;Placebo
47 Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Omega-3 Supplementation With Docosahexaenoic Acid (DHA) on Tardive Dyskinesia Unknown status NCT00621634 Phase 2
48 Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease Unknown status NCT02439125 Phase 2 Eltoprazine HCl;Placebo
49 Randomized Controlled Trial of Laparoscopic Cholecystectomy vs. Non-operative Treatment for Gallbladder Dyskinesia Unknown status NCT02195115 Phase 2 amitriptyline
50 A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Severe L-dopa Induced Dyskinesias Completed NCT00888004 Phase 2 AFQ056;Placebo

Search NIH Clinical Center for Lingual-Facial-Buccal Dyskinesia

Cochrane evidence based reviews: dyskinesias

Genetic Tests for Lingual-Facial-Buccal Dyskinesia

Genetic tests related to Lingual-Facial-Buccal Dyskinesia:

# Genetic test Affiliating Genes
1 Orofacial Dyskinesia 28

Anatomical Context for Lingual-Facial-Buccal Dyskinesia

Organs/tissues related to Lingual-Facial-Buccal Dyskinesia:

MalaCards : Subthalamic Nucleus, Lung, Brain, Tongue, Globus Pallidus, Heart, Liver

Publications for Lingual-Facial-Buccal Dyskinesia

Articles related to Lingual-Facial-Buccal Dyskinesia:

(show top 50) (show all 312)
# Title Authors PMID Year
1
Movement disorders of the mouth: a review of the common phenomenologies. 62
35904592 2022
2
Orofacial dyskinesia in a patient with autoimmune encephalitis and voltagegated potassium channel complex antibodies 62
35894674 2022
3
Orofacial dyskinesia with choreoathetoid movements caused by brainstem encephalitis: A rare complication of SARS-CoV-2-related multisystem inflammatory syndrome in children. 62
35148008 2022
4
Bilateral Focused Ultrasound Pallidotomy for Parkinson-Related Facial Dyskinesia-A Case Report. 62
35844284 2022
5
Compound Heterozygous VPS13A Variants in a Patient with Neuroacanthocytosis: A Case Report and Review of the Literature. 62
35075478 2022
6
Orofacial Dyskinesia and Intractable Hiccups in a Patient with Varicella-Zoster Virus Encephalomyelitis. 62
35676037 2022
7
Understanding and management of anti-N-methyl-D-aspartate receptor encephalitis from a child psychiatry perspective: report of five cases. 62
35672904 2022
8
On the quest for hidden ovarian teratomas in therapy-refractory anti-NMDA receptor encephalitis: a case report. 62
35462557 2022
9
Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones. 62
34854012 2022
10
A case of QARS1 associated epileptic encephalopathy and review of epilepsy in aminoacyl-tRNA synthetase disorders. 62
34774383 2022
11
PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. 62
34048863 2021
12
Anti-N-methyl-D-aspartate receptor encephalitis: An observational and comparative study in Mexican children and adults. 62
34688092 2021
13
Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis in Children and Adolescents: A Systematic Review and Quantitative Analysis of Reported Cases. 62
34777507 2021
14
Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report. 62
34357702 2021
15
Long-acting Methylphenidate Induced Transient Orofacial Dyskinesia and Upper Extremity Choreoathetosis: A Case Report. 62
34461003 2021
16
Masked Tardive Dyskinesia in the Coronavirus Disease 2019 Era. 62
34540401 2021
17
Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia. 62
33523404 2021
18
SLC20A2 mutation manifesting as very late-onset orofacial dyskinesia. 62
33452934 2021
19
Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia. 62
33857021 2021
20
The challenge of diagnosing and successfully treating anti-NMDA receptor encephalitis in a toddler. 62
33879947 2021
21
Effects of CATECHIN on reserpine-induced vacuous chewing movements: behavioral and biochemical analysis. 62
32725283 2020
22
Orofacial dyskinesia post resection of pineal gland tumor. 62
33391638 2020
23
Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report. 62
32761113 2020
24
Late-onset oro-facial dyskinesia in Spinocerebellar Ataxia type 2: a case report. 62
32340607 2020
25
Combined Dendritic and Axonal Deterioration Are Responsible for Motoneuronopathy in Patient-Derived Neuronal Cell Models of Chorea-Acanthocytosis. 62
32151030 2020
26
Resolution of tardive tremor after bilateral subthalamic nucleus deep brain stimulation placement. 62
33408929 2020
27
Frontotemporal brain sagging syndrome: Craniospinal hypovolemia secondary to a T6-T7 cerebrospinal fluid-venous fistula. 62
32905237 2020
28
Orofacial Dyskinesia in a Young Man. 62
31545336 2019
29
[Acute neuropsychiatry: a confused patient and a puzzled doctor]. 62
32073794 2019
30
Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances. 62
31374223 2019
31
Correction to: Novel mutations in KMT2B offer pathophysiological insights on childhood-onset progressive dystonia. 62
31388109 2019
32
Novel mutations in KMT2B offer pathophysiological insights into childhood-onset progressive dystonia. 62
31165786 2019
33
18F-FDG PET/CT: an unexpected case of Huntington's disease. 62
31043171 2019
34
Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. 62
30642806 2019
35
Anti-N-methyl-d-aspartate receptor encephalitis during pregnancy: A case report. 62
30788880 2019
36
Clinical Profile and Neuropsychiatric Outcome in Children with Anti-NMDAR Encephalitis. 62
30955001 2019
37
Severe tooth loss secondary to orofacial dyskinesias in anti-NMDA receptor encephalitis. 62
30846455 2019
38
A review for the pharmacological effect of lycopene in central nervous system disorders. 62
30616078 2019
39
Infectious Trigger for Autoimmune Encephalitis: A Case Report and Literature Review. 62
31781432 2019
40
Possible nitric oxide mechanism involved in the protective effect of L-theanine on haloperidol-induced orofacial dyskinesia. 62
30942195 2019
41
TLE1, a key player in neurogenesis, a new candidate gene for autosomal recessive postnatal microcephaly. 62
29758293 2018
42
Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. 62
30217539 2018
43
Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy. 62
28328695 2018
44
Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats. 62
28641484 2018
45
L-Theanine Decreases Orofacial Dyskinesia Induced by Reserpine in Rats. 62
29629512 2018
46
Anti-NMDA receptor encephalitis: still unknown and underdiagnosed by physicians and especially by psychiatrists? 62
29050531 2018
47
Dexmethylphenidate Extended Release-Associated Orofacial Dyskinesia in an Adolescent with Autism Spectrum Disorder After Prolonged Use. 62
29781724 2018
48
Pediatric NMDAR encephalitis: A single center observation study with a closer look at movement disorders. 62
29396169 2018
49
Acute-onset Orofacial Dyskinesia with a Single Low Dose of Oral Flupentixol: A Case Report. 62
29962578 2018
50
Protective Effect of L-Theanine on Haloperidol-Induced Orofacial. 62
29374957 2018

Variations for Lingual-Facial-Buccal Dyskinesia

ClinVar genetic disease variations for Lingual-Facial-Buccal Dyskinesia:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HERC2 NM_004667.6(HERC2):c.5045A>G (p.Asn1682Ser) SNV Uncertain Significance
599009 rs140073033 GRCh37: 15:28474681-28474681
GRCh38: 15:28229535-28229535
2 RYR1 NM_000540.3(RYR1):c.1312G>C (p.Glu438Gln) SNV Uncertain Significance
599010 rs765668209 GRCh37: 19:38943526-38943526
GRCh38: 19:38452886-38452886

Expression for Lingual-Facial-Buccal Dyskinesia

Search GEO for disease gene expression data for Lingual-Facial-Buccal Dyskinesia.

Pathways for Lingual-Facial-Buccal Dyskinesia

GO Terms for Lingual-Facial-Buccal Dyskinesia

Cellular components related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.35 CNTNAP2 DRD2 DRD3 GRIN1 GRIN2B HTR2C
2 membrane GO:0016020 10.35 CNTNAP2 DRD2 DRD3 GRIN1 GRIN2B HTR2C
3 plasma membrane GO:0005887 10.03 DRD2 DRD3 GRIN1 GRIN2B HTR2C SLC18A2
4 plasma membrane GO:0005886 10.03 DRD2 DRD3 GRIN1 GRIN2B HTR2C SLC18A2
5 postsynaptic membrane GO:0045211 9.8 SLC6A3 GRIN2B GRIN1 DRD2
6 NMDA selective glutamate receptor complex GO:0017146 9.56 GRIN2B GRIN1
7 dopaminergic synapse GO:0098691 9.1 SLC6A3 SLC18A2 DRD2

Biological processes related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 social behavior GO:0035176 10.05 VPS13A DRD3 CNTNAP2
2 visual learning GO:0008542 10.02 GRIN1 DRD3 DRD2
3 cellular calcium ion homeostasis GO:0006874 10 KEL HTR2C DRD3 DRD2
4 G protein-coupled receptor internalization GO:0002031 9.94 DRD3 DRD2
5 excitatory chemical synaptic transmission GO:0098976 9.93 GRIN2B GRIN1
6 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.92 DRD3 DRD2
7 calcium ion transmembrane import into cytosol GO:0097553 9.92 GRIN2B GRIN1
8 positive regulation of cysteine-type endopeptidase activity GO:2001056 9.91 GRIN2B GRIN1
9 negative regulation of cytosolic calcium ion concentration GO:0051481 9.91 DRD3 DRD2
10 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.91 HTR2C DRD3 DRD2
11 monoamine transport GO:0015844 9.9 SLC6A3 SLC18A2
12 adenohypophysis development GO:0021984 9.89 DRD2 SLC6A3
13 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.88 DRD2 DRD3
14 response to cocaine GO:0042220 9.88 SLC6A3 DRD3 DRD2
15 hyaloid vascular plexus regression GO:1990384 9.87 SLC6A3 DRD2
16 regulation of monoatomic cation transmembrane transport GO:1904062 9.86 GRIN2B GRIN1
17 dopamine uptake involved in synaptic transmission GO:0051583 9.84 SLC6A3 DRD2
18 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.83 DRD2 DRD3
19 phosphate ion transport GO:0006817 9.82 XPR1 SLC20A2
20 dopamine transport GO:0015872 9.81 SLC18A2 SLC6A3
21 regulation of potassium ion transport GO:0043266 9.8 DRD2 DRD3
22 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.78 DRD2 DRD3
23 response to histamine GO:0034776 9.67 DRD2 DRD3
24 regulation of biological quality GO:0065008 9.63 DRD3 DRD2
25 prepulse inhibition GO:0060134 9.63 SLC6A3 DRD3 DRD2
26 acid secretion GO:0046717 9.62 DRD2 DRD3
27 regulation of locomotion involved in locomotory behavior GO:0090325 9.56 DRD3 DRD2
28 response to ethanol GO:0045471 9.56 SLC6A3 GRIN2B GRIN1 DRD3 DRD2
29 locomotory behavior GO:0007626 9.4 VPS13A SLC6A3 SLC18A2 HTR2C DRD3 DRD2

Molecular functions related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutamate binding GO:0016595 9.71 GRIN2B GRIN1
2 monoamine transmembrane transporter activity GO:0008504 9.67 SLC6A3 SLC18A2
3 NMDA glutamate receptor activity GO:0004972 9.62 GRIN2B GRIN1
4 dopamine binding GO:0035240 9.56 SLC6A3 DRD2
5 glutamate-gated calcium ion channel activity GO:0022849 9.46 GRIN2B GRIN1
6 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD3 DRD2
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.92 DRD3 DRD2

Sources for Lingual-Facial-Buccal Dyskinesia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....